Application Article: Developing Revolutionary New Drugs from Monoclonal Antibodies that Target GPCRs
Antibodies are proteins which specifically recognize antigens in immunological responses. Antibody-based drugs have high drug efficacies and minimal side effects because they only recognize and bind specifically to the target molecules. “Antibodies targeting GPCRs makes it possible to directly intervene the transmission of information in diseases involving GPCRs signaling; therefore, discovery of such antibodies can lead to development of extremely effective drugs for these diseases.” said Mr. Takayama.
Download the article to read how Dr. Kiyoshi Takayama, President of NB Health Laboratory, is aiming to discover and manufacture revolutionary antibody-based biological drugs that target GPCRs.
Learn more about Sartorius solutions for mAb Discovery & Development at www.sartorius.com/mab-oncology.